Skip to content

TriGUARD 3 TransCranial Doppler (TCD) Ultrasound Study: A prospective, randomized, real-time evaluation of blood filtration with the TriGUARD 3 Embolic Protection Device Using TCD During Transcatheter Aortic Valve Implantation (TAVI).

TriGUARD 3 TransCranial Doppler (TCD) Ultrasound Study: A prospective, randomized, real-time evaluation of blood filtration with the TriGUARD 3 Embolic Protection Device Using TCD During Transcatheter Aortic Valve Implantation (TAVI). - Triguard 3 - TCD study

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON49111
Enrollment
30
Registered
2020-03-24
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

paralysis Stroke

Interventions

Sponsors

Keystone Heart
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. The patient must be * 18 years of age. 2. The patient meets indications for TAVI procedure. 3. The patient has been informed of the nature of the study, agrees to its provisions and has been provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) 4. The patient is willing to comply with specified follow-up evaluations.

Exclusion criteria

Exclusion criteria: 1.Patients undergoing TAVI via the trans-axillary, transapical, subclavian, or direct aortic route 2 Patients with impaired renal function (estimated Glomerular Filtration Rate [eGFR]

Design outcomes

Primary

MeasureTime frame
Primary endpoint: * High-intensity transient signals detected by transcranial Doppler (TCD), during the procedure.

Secondary

MeasureTime frame
Secondary Performance Endpoints: * Successful device deployment, defined as ability to access the aortic arch with the TriGUARD* 3 delivery catheter and deploy the device from the delivery catheter into the aortic arch. * Successful Device positioning, defined as ability to position the TriGUARD* 3 device in the aortic arch to cover all major cerebral arteries * Successful device retrieval, defined as ability to retrieve the TriGUARD* 3 device and remove the intact delivery system * Device success, defined as successful device deployment, successful device positioning, complete 3-vessel coverage throughout the procedure, and successful device retrieval. Secondary Safety Endpoints * Cardiovascular mortality * Ischemic stroke o Disabling o Non-disabling * Life threatening (or disabling) bleeding * Acute kidney injury (Stage 3) * Major vascular complications (excluding TAVI access site-related complications) Mortality: * All-cause mortality o Cardiovascular mortality o Non-cardiovascular mortality Stroke (VARC-2 defined), sub-classified as ischemic and hemorrhagic * All stroke * Transient ischemic attack (TIA) Bleeding Complications: * Life-threatening bleeding (VARC-2) * Major bleeding related to TriGUARD 3 Acute Kidney Injury (AKI Classification): Vascular Complications: * Major vascular complications related to TriGUARD 3 * Major vascular complications related to TAVI

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)